stockrow
Monday 9 November 2026
Export ANTX’s income statement to Excel — free account
AN2 Therapeutics, Inc.
ANTX- EPS
- +14.3%
- Free cash flow
- +7.91%
Quarter to June 2026, against a year earlier
4.00
0.04
+1.01%
Follow ANTX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | 0.00 | — | — | — | 0.00 | — | ||||||
| EBT | — | — | — | (6) | (14) | (22) | (41) | (65) | (51) | (35) | (36) | +35.7% | ||||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | — | (6) | (14) | (22) | (41) | (65) | (51) | (35) | (36) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | (0.31) | (5.30) | (10.64) | (2.79) | (2.74) | (1.72) | (1.16) | (1.07) | +24.6% | ||||||
| Cash flow | — | — | — | (0.13) | (2.09) | (7.76) | (2.18) | (2.26) | (1.65) | (0.99) | (0.69) | +39.7% | ||||||
| Capex | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | (0.13) | (2.09) | (7.76) | (2.18) | (2.26) | (1.65) | (0.99) | (0.69) | +39.7% | ||||||
| Book value | — | — | — | 0.26 | 1.07 | 23.47 | 6.22 | 5.28 | 2.74 | 1.76 | 1.70 | +37.8% | ||||||
| Shares, m | — | — | — | 19 | 3 | 3 | 15 | 24 | 30 | 30 | 35 | +8.3% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (2) | (5) | (20) | (33) | (53) | (49) | (30) | (31) | +51.3% | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Free cash flow | — | — | — | (2) | (5) | (20) | (33) | (53) | (49) | (30) | (31) | +51.3% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | 6 | 3 | 57 | 91 | 96 | 76 | 51 | 74 | +44.9% | |||||
| Net debt | — | — | — | (6) | (4) | (59) | (96) | (107) | (84) | (58) | (78) | +47.7% | ||||||
| Shareholders’ equity | — | — | — | 5 | 3 | 62 | 95 | 125 | 82 | 53 | 76 | +49.2% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | (201.19) | (293.62) | (80.68) | (50.96) | (53.65) | (44.47) | (45.67) | (46.06) | +155.5 pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | (402.14) | 0.00 | (250.04) | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | 43.91 | 111.67 | 82.85 | (178.38) | (58.83) | (49.69) | (52.14) | (50.12) | (96.0) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | 22 | 36 | 41 | 22 | 21 | — | (1.2%) | |||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 25 Oct 2026
AN2 Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CNTN Canton Strategic Holdings, Inc. | $164.1M | — (loss-making) | — | — | n/m | −600.39% (below 0%: shrinking) | 100.00% | (80.37%) | Compare |
| IPHA Innate Pharma S.A. Sponsored ADR | $160.9M | — (loss-making) | — | +246.29% (above 0%: growing) | +106.08% (above 0%: growing) | −929.03% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| STRO Sutro Biopharma, Inc. | $159.5M | — (loss-making) | — (loss-making) | −84.57% (below 0%: shrinking) | n/m | +14.55% (above 0%: growing) | 100.00% | (303.77%) | Compare |
| ANTX AN2 Therapeutics, Inc. | $150.9M | — (loss-making) | — | — | n/m | +7.91% (above 0%: growing) | 0.00% | 0.00% | |
| MGNX MacroGenics, Inc. | $148.4M | — (loss-making) | — (loss-making) | +47.62% (above 0%: growing) | n/m | +12.88% (above 0%: growing) | 100.00% | (42.19%) | Compare |
| SION Sionna Therapeutics, Inc. | $148.3M | — (loss-making) | — | — | n/m | −22.40% (below 0%: shrinking) | — | 0.00% | Compare |
| NGEN NervGen Pharma Corp. | $143.1M | — (loss-making) | — | — | n/m | −48.10% (below 0%: shrinking) | — | 0.00% | Compare |
| VRXA Veraxa Biotech AG | $140.4M | — | — | — | — | — | — | — | Compare |
| INO Inovio Pharmaceuticals, Inc. | $125.6M | — (loss-making) | — (loss-making) | −83.19% (below 0%: shrinking) | n/m | +13.41% (above 0%: growing) | 100.00% | 0.00% | Compare |
| Median of peers | $148.4M | — | — | −17.78% | — | −22.40% | 100.00% | 0.00% |